A Toronto-based artificial intelligence imaging company is joining a new global alliance aimed at closing the widening gap in care for people living with congenital heart disease, a condition that now affects an estimated 16 million people worldwide.
Growing Crisis in Congenital Heart Care
Congenital heart disease remains the most common birth defect globally, with prevalence rising from 11.8 million cases three decades ago to approximately 16 million today, according to the World Heart Federation's World Heart Report 2026. The condition now affects about 2% of live births. However, the same report highlights a stark disparity: more than 90% of children in lower- and middle-income countries lack timely access to appropriate care. This paradox stems from medical advances that allow more patients to survive into adulthood, while diagnostic and monitoring tools remain unevenly distributed.
Ventripoint Diagnostics Joins Global Alliance
On June 15, 2026, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTCQB: VPTDF) announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA). This industry coalition aims to accelerate the development, commercialization, and global adoption of congenital cardiovascular technologies. As part of its initial efforts, the alliance will help fund and deploy four of Ventripoint's VMS+ cardiac imaging units to directly support the congenital heart disease community and expand access to advanced diagnostic care.
Why Congenital Heart Disease Is a Uniquely Hard Problem
Congenital heart disease encompasses a broad range of structural heart defects present from birth, varying from minor to life-threatening. Two factors make it particularly challenging from a diagnostic perspective. First, it is a lifelong condition: thanks to decades of surgical and medical progress, most children born with congenital heart defects now survive into adulthood, creating a large and growing population requiring structured, individualized follow-up for life. Second, the anatomy is often complex and irregular—surgically reconstructed or abnormally developed hearts do not conform to the geometric assumptions built into many conventional imaging tools, making accurate measurement inherently difficult.
This combination—a lifelong need for precise, repeated monitoring of anatomy that resists easy measurement—is precisely where imaging technology plays a critical role. The European Society of Cardiology's guidelines for adult congenital heart disease classify the condition as a chronic illness requiring lifelong individualized follow-up and identify echocardiography as the key modality for longitudinal assessment of heart function. However, the gold standard for the most accurate measurements, cardiac MRI, is expensive, slow, and scarce—especially in underserved regions where the access gap is widest. The field has long needed a way to deliver high-accuracy cardiac measurement at the point of care, without requiring an MRI suite.
Ventripoint's Approach: MRI-Level Accuracy from a Standard Echo
Ventripoint's flagship platform, VMS+, is built to address this need. The technology uses artificial intelligence to transform standard 2D echocardiograms—among the most widely available imaging exams worldwide—into highly accurate 3D models of all four heart chambers, delivering what the company describes as cardiac-MRI-level measurement accuracy at the point of care. For congenital heart patients, whose complex anatomy often defeats traditional imaging, this capability is especially relevant. The platform is powered by Ventripoint's proprietary Knowledge-Based Reconstruction technology, developed over roughly a decade, and is designed to run on existing ultrasound systems from any vendor, allowing hospitals and clinics to expand advanced cardiac imaging without purchasing new scanners.
